JP2024536718A - Ｍａｇｌ阻害剤 - Google Patents

Ｍａｇｌ阻害剤 Download PDF

Info

Publication number
JP2024536718A
JP2024536718A JP2024513990A JP2024513990A JP2024536718A JP 2024536718 A JP2024536718 A JP 2024536718A JP 2024513990 A JP2024513990 A JP 2024513990A JP 2024513990 A JP2024513990 A JP 2024513990A JP 2024536718 A JP2024536718 A JP 2024536718A
Authority
JP
Japan
Prior art keywords
compound
pharma
magl
acceptable salt
ceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513990A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536718A5 (enExample
Inventor
ゴッビ，ルカ・クラウディオ
グレター，ウーヴェ・ミヒャエル
ヘ，インファン
クーン，ベルント
ムゥ，リンジン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Eidgenoessische Technische Hochschule Zurich ETHZ
Original Assignee
F Hoffmann La Roche AG
Eidgenoessische Technische Hochschule Zurich ETHZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG, Eidgenoessische Technische Hochschule Zurich ETHZ filed Critical F Hoffmann La Roche AG
Publication of JP2024536718A publication Critical patent/JP2024536718A/ja
Publication of JP2024536718A5 publication Critical patent/JP2024536718A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/918—Carboxylic ester hydrolases (3.1.1)
    • G01N2333/92—Triglyceride splitting, e.g. by means of lipase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
JP2024513990A 2021-09-03 2022-09-01 Ｍａｇｌ阻害剤 Pending JP2024536718A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21194695 2021-09-03
EP21194695.9 2021-09-03
PCT/EP2022/074263 WO2023031311A1 (en) 2021-09-03 2022-09-01 Magl inhibitors

Publications (2)

Publication Number Publication Date
JP2024536718A true JP2024536718A (ja) 2024-10-08
JP2024536718A5 JP2024536718A5 (enExample) 2025-09-03

Family

ID=77640389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513990A Pending JP2024536718A (ja) 2021-09-03 2022-09-01 Ｍａｇｌ阻害剤

Country Status (5)

Country Link
US (1) US20240270725A1 (enExample)
EP (1) EP4395840A1 (enExample)
JP (1) JP2024536718A (enExample)
CN (1) CN117836014A (enExample)
WO (1) WO2023031311A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015099196A1 (en) * 2013-12-26 2015-07-02 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors

Also Published As

Publication number Publication date
US20240270725A1 (en) 2024-08-15
WO2023031311A1 (en) 2023-03-09
CN117836014A (zh) 2024-04-05
EP4395840A1 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
KR101123178B1 (ko) 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
Wang et al. Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain
Skaddan et al. The synthesis and in vivo evaluation of [18F] PF-9811: a novel PET ligand for imaging brain fatty acid amide hydrolase (FAAH)
US20240327361A1 (en) Radiolabeled compositions and methods of use thereof
BRPI0808503B1 (pt) Composto, uso de um composto, e, composição farmacêutica
US20240270725A1 (en) Magl inhibitors
US20210017133A1 (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
Xiao et al. Radiosynthesis and evaluation of a novel 18F-labeled tracer for PET imaging of glycogen synthase kinase 3
CA2911307C (en) Use of fluorinated derivatives of 4-aminopyridine in therapeutics and medical imaging
HK40102563A (zh) Magl抑制剂
Zhong et al. PET imaging assist investigation of HDAC6 expression change in MDD and evaluating antidepressant efficacy of a newly developed HDAC6 inhibitor
WO2024123700A1 (en) Histone deacetylase inhibitors
Rong et al. Development of a novel 18F-labeled reversible-binding radioligand for imaging monoacylglycerol lipase with positron emission tomography
Mori et al. Radiosynthesis and evaluation of 4-(6-[18 F] Fluoro-4-(5-isopropoxy-1 H-indazol-3-yl) pyridin-2-yl) morpholine as a novel radiotracer candidate targeting leucine-rich repeat kinase 2
JP7456641B2 (ja) Ｐｅｔ放射性トレーサーとしての［１８ｆ］標識ベンゾチアゾール誘導体
CN102223900A (zh) 用于多巴胺d2受体的成像配体
US20170174632A1 (en) 4-oxo-1, 4-dihydroquinoline-3-carboxamide as selective ligand for cannabinoid receptor 2 for diagnosis and therapy
KR20100112423A (ko) 2-아릴나프탈렌, 2-아릴퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
Huang et al. The design, synthesis and evaluation of the first carbon-11 positron emission tomography radiotracer for ASK1 imaging
Kopka et al. 18F-labelled cardiac PET tracers: selected probes for the molecular imaging of transporters, receptors and proteases
Huang et al. Development of a new 18F-labeled PET tracer for potential application to HDAC2 neuroimaging
US20260027242A1 (en) Pet radioligands for imaging glutaminyl cyclase activity
US20240174608A1 (en) Compounds for brain imaging
CN109476602B (zh) 用于可溶性环氧化物水解酶(sEH)的PET成像的18F-FNDP
Fantoni Development and Evaluation of a Library of Novel 18F-labelled PET Tracers Targeting the P2X7 Receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250826